Summary
One hundred and twenty-three rheumatoid patients were commenced on one of the three second-line agents: sodium aurothiomalate (GST), penicillamine (P), or levamisole (L). After four years, 39% of the GST group, 20% of the penicillamine group, and 8% of the levamisole group remained on the original agent. Fifty five % of patients, however, were receiving some second-line agent at four years, and patients showed an improvement in inflammatory indices irrespective of whether or not they were still receiving second-line therapy. It is unclear whether this improvement reflects the natural history of the disease, or the fact that regular clinic attendance identifies patients who require further second-line therapy following cessation of the initial agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fraser, T.N. Gold treatment in rheumatoid arthritis. Ann Rheum Dis, 1945, 4, 71–75.
Multicentre Trial Group. Controlled trial of D(-) penicillamine in severe rheumatoid arthritis. Lancet, 1973, i, 275–280.
Day, A.T., Galding, J.R., Lee, P.N., Butterworth, A.D. Penicillamine in rheumatoid disease: a long-term study. Br Med J, 1974, 1, 180–183.
The Research Subcommittee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: final report of a multicentre trial. Ann Rheum Dis, 1961, 20, 315–334.
Capell, H.A., Hunter, J.A., Rennie, J.A.N., Murdoch, R.M. Levamisole — a possible alternative to gold and penicillamine in the long-term treatment of rheumatoid arthritis? J Rheumatol, 1981, 8, 730–740.
Veys, E.M., Mielants, H., Verbruggen, G. et al. Levamisole as basic treatment of rheumatoid arthritis: long-term evaluation. J Rheumatol, 1981, 8, 45–56.
Rothermich, N.O., Philips, V.K., Bergen, W., Thomas, M.H. Chrysotherapy, a prospective study. Arthritis Rheum, 1976, 19, 1321–1327.
Pullar, T., Hunter, J.A., Capell, H.A. Does second-line therapy affect the radiological progression of rheumatoid arthritis? Ann Rheum Dis, 1984, 43, 18–23.
Srinivasan, R., Miller, B.L., Paulus, H.E. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum, 1979, 22, 105–110.
Sharp, J.T., Lidsky, M.D., Duffy, J. Clinical responses during gold therapy for rheumatoid arthritis. Arthritis Rheum 1982, 25, 540–549.
Sigler, J.W., Bluhm, G.B., Duncan, H. et al. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Int Med, 1974, 80, 21–26.
Gibson, T., Huskisson, E.C., Wajtulewski, J.A. et al. Evidence that D-penicillamine alters the course of rheumatoid arthritis. Rheumatol Rehabil, 1976, 15, 211–215.
Pullar, T., Hunter, J.A., Capell, H.A. Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J, 1983, 287, 1102–1104.
Teh, L.G., Madhok, R., Capell, H.A. Ketotifen in rheumatoid arthritis. Br J Clin Pharmacol, 1984, 17, 157–159.
Lewis, D., Capell, H.A. Is auranofin preferable to gold sodium aurathiomalate in the management of rheumatoid arthritis ? In: Auranofin. Netherlands: Excerpta Medica, 1983, 147–154.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pullar, T., Hunter, J.A. & Capell, H.A. Second line therapy in rheumatoid arthritis — A four year prospective study. Clin Rheumatol 4, 133–142 (1985). https://doi.org/10.1007/BF02032283
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02032283